Kui Su

发表

EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma

Changhong Ke, Yue Lin, Z. Du, 2022, Journal of Molecular Medicine.

Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy

X. Yuan, Minghui Yang, Shuyi Li, 2022, Cancers.

TRAIL‐Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582)

Changhong Ke, Yue Lin, Z. Du, 2021, Advanced healthcare materials.

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

Changhong Ke, Yue Lin, Z. Du, 2020, Cancers.

Targeting the Akt/PI3K/mTOR signaling pathway for complete eradication of keloid disease by sunitinib

Shuyi Li, Huan Hou, Kui Su, 2022, Apoptosis.

Comparative Study of High-throughput Screening Models for Anti-hyperpigmentation Compounds

Kui Su, Wen Tan, Shaojuan Wu, 2022, Brazilian Archives of Biology and Technology.

Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.

Changhong Ke, Z. Du, Y. He, 2022, Acta histochemica.

Improved Prediction of Knee Osteoarthritis by the Machine Learning Model XGBoost

Tianwang Li, Yukai Huang, Kui Su, 2023, Indian Journal of Orthopaedics.

Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway

Wei Zhou, Changhong Ke, Shuyi Li, 2023, Apoptosis.